Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)
PCSK9is reduce Lp(a) levels by an average of 27%. Mean percent change in low-density lipoprotein cholesterol and apolipoprotein B were associated with treatment effect.
Authors
- Genquen Philip Carado (ORCID: https://orcid.org/0000-0001-6793-8114)
- Vincent Anthony Songheng Tang (ORCID: https://orcid.org/0000-0002-2061-7740)
- Sung Whoy (ORCID: https://orcid.org/0000-0002-2487-2802)
- Martha Gulati (ORCID: https://orcid.org/0000-0003-0735-9756)
- John Vincent Magalong (ORCID: https://orcid.org/0000-0002-2276-0647)
- Frederick Berro Rivera (ORCID: https://orcid.org/0000-0001-9100-0724)
- Nishant Shah (ORCID: https://orcid.org/0000-0002-2666-7132)
- Byambaa Enkhmaa (ORCID: https://orcid.org/0000-0002-1429-6864)
- Neha Jadeja Pagidipati (ORCID: https://orcid.org/0000-0002-5004-8868)
- Mary Grace Enriquez
- Cruz Linnaeus Louisse
Institutions
- Lincoln Medical Center (US)
- Philippine General Hospital (PH)
- Clinical Research Institute (US)
- Duke Medical Center (US)
- Cedars-Sinai Smidt Heart Institute (US)
- University of the Philippines Manila (PH)
- University of California, Davis (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1016/j.jacadv.2024.101549
- Citations
- 14
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 28.09